Financial Performance - Grant income for the years ended December 31, 2020 and 2019 was approximately $0.2 million and $0.5 million, respectively, indicating a decrease of approximately 60% in 2020 compared to 2019[535]. - General and Administrative (G&A) expenses for the years ended December 31, 2020 and 2019 were approximately $5.5 million and $3.6 million, respectively, reflecting an increase of approximately 52.8% in 2020[537]. - The increase in G&A expenses in 2020 was primarily due to a $1.2 million increase in stock-based compensation expense and a $0.5 million increase in salaries and recruiting related expenses[537]. - Investment income decreased from $94,791 in 2019 to $32,943 in 2020, a decline of approximately 65.3% due to reduced interest rates[540]. - The company reported a net loss of approximately $13.7 million for the year ended December 31, 2020, compared to a net loss of $10.4 million in 2019[548]. - Cash used in operating activities rose to approximately $10.1 million in 2020 from $6.8 million in 2019, an increase of about 48.5%[548]. - The company raised approximately $33.0 million from the sale of common stock in 2020, compared to $9.2 million in 2019, marking an increase of about 258.7%[550]. Research and Development - Research and Development (R&D) expenses increased from approximately $5.1 million in 2019 to $8.5 million in 2020, a rise of about 66.7%[539]. - R&D expenses primarily include salaries, clinical trial costs, and manufacturing costs, with expenses recognized as incurred[583]. - The accrual policy for R&D activities aims to match expenses with actual services received, with variations in payment flows due to contract negotiations[585]. - The company monitors activity levels through communication with CROs and vendors, ensuring expenses align with budgeted amounts[584]. - The clinical trial accrual process is designed to reflect appropriate expenses in financial statements based on the progress of trials[592]. Clinical Trials and Product Development - The company has completed the Phase II clinical trial (HOPE-2) for CAP-1002, showing improvements in multiple measures of upper limb, cardiac, and respiratory functions[507]. - The FDA has encouraged the company to conduct a Phase III study for CAP-1002, although discussions regarding the pathway forward are still ongoing[507]. - The INSPIRE trial for CAP-1002 in severe or critical COVID-19 patients is a Phase II, randomized, double-blind, placebo-controlled study enrolling up to 60 patients[509]. - The company is developing two vaccine candidates for COVID-19, including a tripartite exosome-mRNA vaccine, with plans to file an IND by the third quarter of 2021[510]. - The company has submitted an IND for CAP-2003 to investigate its use in patients with Duchenne Muscular Dystrophy (DMD) and is evaluating the next steps for this program[514]. Funding and Grants - The Company received a CIRM Grant Award of approximately $3.4 million for its Phase I/II clinical trial, requiring a co-funding of about $2.3 million from the Company[565]. - As of December 31, 2020, the liability balance for the CIRM Award was approximately $3.4 million, with all milestones completed by June 2019[567]. - The NIH grant for CAP-2003 amounted to approximately $4.2 million, with $0.7 million incurred by June 30, 2019, and the award was closed in Q2 2019[568]. - The Department of Defense grant totaled approximately $2.4 million, with about $2.3 million utilized, and a no-cost extension granted until September 29, 2020[569]. Cash and Investments - Cash, cash equivalents, and marketable securities increased from approximately $9.9 million in 2019 to $32.7 million in 2020, a growth of about 230.5%[544][550]. - The net increase in cash and cash equivalents for 2020 was approximately $28.8 million, compared to a decrease of $646,000 in 2019[547]. - The fair value of cash and cash equivalents as of December 31, 2020, was approximately $32.7 million[598]. - The investment portfolio primarily consists of money market funds and short-term U.S. treasuries, aiming to limit credit exposure and default risk[598]. - The company does not hedge interest rate exposure and believes that a hypothetical 100 basis point change in interest rates would not significantly impact the fair value of its investment portfolio[599]. Stock-Based Compensation - Stock-based compensation expense is recognized over the vesting period, with significant future non-cash compensation expenses expected[591]. - The company accounts for stock options using the Black-Scholes option-pricing model, requiring assumptions about various variables[589].

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants AJ Bergmann – Chief Financial Officer Linda Marbán – Chief Executive Officer Stephen Gould – Executive Consultant Conference Call Participants Michael Okunewitch – Maxim Group Emanuela Branchetti – H.C. Wainwright Alan Leong – BioWatch News Operator Greetings, and welcome to Capricor Therapeutics Fourth Quarter Full Year 2020 Earnings and Corporate Update Call. At this time, all particip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2020 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or other jurisdict ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2020 Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - President, Chief Executive Officer and Director Steve Gould - Executive Consultant Conference Call Participants Emanuela Branchetti - H.C. Wainwright Jason McCarthy - Maxim Group Alan Leong - BioWatch News Operator Greetings, and welcome to the Capricor Therapeutics Inc Third Quarter 2020 Earnings Call. [Operator Instructions]. As ...

Corporate & Investor Presentation Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside NASDAQ: CAPR August 2020 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2020 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or other jurisdiction o ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Naureen Quibria - Maxim Group Alan Leong - BioWatch Operator Greetings, and welcome to the Capricor Therapeutics Second Quarter 2020 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded Thursday, August 6, 2020. I would now lik ...

Capricor Therapeutics Inc. (NASDAQ:CAPR) Q1 2020 Earnings Conference Call May 14, 2020 4:30 PM ET Corporate Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Emanuela Branchetti - H.C. Wainwright Alan Leong - BioWatch Operator Greetings and welcome to the Capricor Therapeutics Inc. First Quarter 2020 Earnings Conference Call. During the presentation, all participations will be in a listen-only mode. Afterward, we will conduct a question-and-answer session. [Operator Instructions ...

1 Capricor Q1 Earnings Call and Corporate Update May 14, 2020 Earnings Call NASDAQ: CAPR Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q þ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2020 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or other jurisdiction ...